Petros Dimitriadis
About
Petros Dimitriadis is a scholar working on Oncology, Immunology and Molecular Biology.
According to data from OpenAlex, Petros Dimitriadis has authored 20 papers receiving a total of 154 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 10 papers in Immunology and 6 papers in Molecular Biology. Recurrent topics in Petros Dimitriadis's work include Cancer Immunotherapy and Biomarkers (18 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (8 papers). Petros Dimitriadis is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (8 papers). Petros Dimitriadis collaborates with scholars based in Netherlands, Australia and United States. Petros Dimitriadis's co-authors include Christian U. Blank, Irene L. M. Reijers, Georgina V. Long, Alexander M. Menzies, Annegien Broeks, Judith M. Versluis, Ruben Lacroix, Disha Rao, Esmée P. Hoefsmit and Richard A. Scolyer and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Annals of Oncology.
In The Last Decade
Petros Dimitriadis
18 papers receiving 154 citations
Peers
Petros Dimitriadis
Susanna Nguy United States
Shaun Tiwari United States
Miya Haruna Japan
Nicole Fuhrich Germany
Heather MacGregor Canada
Shen Lao China
Ayman Ahmed Qatar
Helena Van Damme Belgium
Marie Naigeon France
André Vanoli France
Citations per year, relative to Petros Dimitriadis Petros Dimitriadis (= 1×)
peers
Susanna Nguy
Countries citing papers authored by Petros Dimitriadis
Since
Specialization
Citations
This map shows the geographic impact of Petros Dimitriadis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petros Dimitriadis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petros Dimitriadis more than expected).
Fields of papers citing papers by Petros Dimitriadis
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Petros Dimitriadis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petros Dimitriadis. The network helps show where Petros Dimitriadis may publish in the future.
Co-authorship network of co-authors of Petros Dimitriadis
This figure shows the co-authorship network connecting the top 25 collaborators of Petros Dimitriadis. A scholar is included among the top collaborators of Petros Dimitriadis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petros Dimitriadis. Petros Dimitriadis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dimitriadis, Petros, Irene L. M. Reijers, Alexander M. Menzies, et al.. (2025). Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures. Cancer Immunology Immunotherapy. 74(8). 253–253.
2.
Versluis, Judith M., Alexander M Menzies, Irene L. M. Reijers, et al.. (2025). Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma. Communications Medicine. 5(1). 407–407.
3.
Versluis, Judith M., Petros Dimitriadis, James S. Wilmott, et al.. (2024). Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma. Journal for ImmunoTherapy of Cancer. 12(4). e008125–e008125.
4.
Reijers, Irene L. M., Petros Dimitriadis, Alexander M. Menzies, et al.. (2023). 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. Annals of Oncology. 34. S660–S660.
5.
Hoeijmakers, Lianne, et al.. (2023). 1121P Interferon-gamma (IFNy) gene signature as a predictive biomarker for response in lactate dehydrogenase (LDH) low advanced melanoma patients. Annals of Oncology. 34. S674–S674.
6.
Rao, Disha, Ruben Lacroix, Petros Dimitriadis, et al.. (2023). Acidity‐mediated induction of FoxP3 + regulatory T cells. European Journal of Immunology. 53(6). e2250258–e2250258.
7.
Hoefsmit, Esmée P., Disha Rao, Petros Dimitriadis, et al.. (2023). Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells. Cancer Immunology Research. 11(4). 450–465.
8.
Reijers, Irene L. M., Petros Dimitriadis, Annegien Broeks, et al.. (2023). Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma. Nature Medicine. 29(12). 3090–3099.
9.
Dimitriadis, Petros, Irene L. M. Reijers, Alexander M. Menzies, et al.. (2023). Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.. Journal of Clinical Oncology. 41(16_suppl). 9516–9516.
10.
Reijers, Irene L. M., Petros Dimitriadis, Annegien Broeks, et al.. (2023). The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9558–9558.
11.
Jacoberger-Foissac, Célia, Petros Dimitriadis, Marjolein de Bruijn, et al.. (2022). Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Science Translational Medicine. 14(642). eabj9779–eabj9779.
12.
Rozeman, Elisa A., Judith M. Versluis, Esmée P. Hoefsmit, et al.. (2022). IMPemBra, a phase 2 study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation: Three-year survival data and translational analyses.. Journal of Clinical Oncology. 40(16_suppl). 9552–9552.
13.
Rao, Disha, Ruben Lacroix, Tainá Gomes, et al.. (2022). MeVa2.1.dOVA and MeVa2.2.dOVA: two novel BRAFV600E-driven mouse melanoma cell lines to study tumor immune resistance. Melanoma Research. 33(1). 12–26.
14.
Reijers, Irene L. M., Petros Dimitriadis, Elisa A. Rozeman, et al.. (2022). The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma.. Journal of Clinical Oncology. 40(16_suppl). 9539–9539.
15.
Blank, Christian U., Irene L. M. Reijers, Judith M. Versluis, et al.. (2021). LBA39 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in stage IIIB-D melanoma patients (pts) stratified according to the interferon-gamma signature (IFN-γ sign): The DONIMI study. Annals of Oncology. 32. S1315–S1315.
16.
Versluis, Judith M., Petros Dimitriadis, Joyce Sanders, et al.. (2021). The prognostic value of the interferon-gamma (IFNγ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy.. Journal of Clinical Oncology. 39(15_suppl). 9579–9579.
17.
Reijers, Irene L. M., Petros Dimitriadis, Elisa A. Rozeman, et al.. (2020). Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.. Journal of Clinical Oncology. 38(15_suppl). TPS10087–TPS10087.
18.
Rozeman, Elisa A., Judith M. Versluis, Karolina Sikorska, et al.. (2020). The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.. Journal of Clinical Oncology. 38(15_suppl). 10021–10021.
19.
Dimitriadis, Petros, Oscar Krijgsman, Sten Cornelissen, et al.. (2020). P01.15 Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature – the DONIMI study. A15.2–A16.
20.
Rozeman, Elisa A., Irene L. M. Reijers, Esmée P. Hoefsmit, et al.. (2020). Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.. Journal of Clinical Oncology. 38(15_suppl). 10015–10015.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Susanna Nguy Breakdown of academic impact, for papers by Shaun Tiwari Breakdown of academic impact, for papers by Miya Haruna Breakdown of academic impact, for papers by Nicole Fuhrich Breakdown of academic impact, for papers by Heather MacGregor Breakdown of academic impact, for papers by Shen Lao Breakdown of academic impact, for papers by Ayman Ahmed Breakdown of academic impact, for papers by Helena Van Damme Breakdown of academic impact, for papers by Marie Naigeon Breakdown of academic impact, for papers by André Vanoli